![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization
|
|
|
Reported by Jules Levin
Digestive Disease Week, May 3-6, 2014, Chicago, IL
Anders H. Nyberg1, Kevin M. Chiang2, Zhaoliang Li2, Zobair M. Younossi3, T. Craig Cheetham4, Lisa M. Nyberg1
1Hepatology Research, Kaiser Permanente, San Diego, CA, United States; 2Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, United States; 3Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, United States; 4Kaiser Permanente Department of Research and Evaluation, Pasadena, CA
![DDW1.gif](../images/050514/050514-10/DDW1.gif)
![DDW2.gif](../images/050514/050514-10/DDW2.gif)
![DDW3.gif](../images/050514/050514-10/DDW3.gif)
![DDW4.gif](../images/050514/050514-10/DDW4.gif)
![DDW5.gif](../images/050514/050514-10/DDW5.gif)
![DDW6.gif](../images/050514/050514-10/DDW6.gif)
![DDW7.gif](../images/050514/050514-10/DDW7.gif)
![DDW8.gif](../images/050514/050514-10/DDW8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|